Compare Regeneron Pharmaceuticals Inc (REGN) vs Western Union Co (WU) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.

Western Union (WU) trades at $7.00, down 2.51% recently, with a bearish technical signal and neutral oscillators. Key financials show a P/E of 5.65 and net income margin of 9.79%, but revenue has declined from $4.5B in 2022 to $4.05B in 2025. Recent news highlights a $200M cost-cutting plan and the pending Intermex acquisition, which faces regulatory hurdles. Analyst consensus is mixed, with a $7.14 price target and a 'Strong Sell' rating from some firms.

The outlook for WU is cautious due to declining revenue, integration risks from acquisitions, and competitive pressures. Opportunities include potential savings from efficiency initiatives and dividend yield appeal, but risks like margin pressure and regulatory delays could hinder recovery. Investors should weigh cost-cutting benefits against fundamental weaknesses in the money transfer sector.